Cellular senescence in cancer treatment: friend or foe?
Open accessThe DOI matches its OpenAlex record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Damage to DNA, the prime target of anticancer therapy, triggers programmed cellular responses. In addition to apoptosis, therapy-mediated premature senescence has been identified as another drug-responsive program that impacts the outcome of cancer therapy. Here, we discuss whether induction of senescence is a beneficial or, rather, a detrimental consequence of the therapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The serial cultivation of human diploid cell strains
Hayflick, L., & Moorhead, P. S. (1961) · Experimental Cell Research · doi:10.1016/0014-4827(61)90192-6 · Cited by 8,508 · cited 1×
“Drug-inducible senescence is a p53and p16INK4a-controlled program Premature senescence recapitulates cellular and molecular features of replicative senescence (7), which is a safeguard program that limits the growth potential, but not necessarily the viability, of a dividing cell as a consequence of the progressive sh…”
BackgroundOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 2×
“Comparable to p53, which functions as a fail-safe mediator, the cyclin-dependent kinase (CDK) inhibitor p16INK4a has been implicated in both response to DNA damage and control of stress-induced senescence (1, 4, 28, 29).”
BackgroundGenomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Döhner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Kröber, A., Bullinger, L., Döhner, K., Bentz, M., & Lichter, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012283432602 · Cited by 3,318
p53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
Narita, M., Nuñez, S., Heard, E., Narita, M., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. J., & Lowe, S. W. (2003) · Cell · doi:10.1016/s0092-8674(03)00401-x · Cited by 2,278 · cited 1×
“Although the molecular mechanisms underlying the senescent phenotype remain largely unknown, there is increasing evidence that formation of heterochromatin in the vicinity of promoters that control gene expression related to cellcycle progression might be implicated in the maintenance of an irreversible growth arrest…”
BackgroundCell cycle checkpoint signaling through the ATM and ATR kinases
Abraham, R. T. (2001) · Genes & Development · doi:10.1101/gad.914401 · Cited by 1,966
Savill, J. S., Wyllie, A. H., Henson, J. E., Walport, M. J., Henson, P. M., & Haslett, C. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113970 · Cited by 1,536
Reversal of human cellular senescence: roles of the p53 and p16 pathways
Beauséjour, C. M., Krtolica, A., Galimi, F., Narita, M., Lowe, S. W., Yaswen, P., & Campisi, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg417 · Cited by 1,457
DNA damage activates p53 through a phosphorylation–acetylation cascade
Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., & Appella, E. (1998) · Genes & Development · doi:10.1101/gad.12.18.2831 · Cited by 1,204 · cited 1×
“Although a cascade of posttranslational modifications has been proposed to control p53 activity in response to DNA damage (20), and different DNA-damaging stimuli such as UV light or γ-irradiation can produce distinguishable signatures of posttranslational p53 modifications (21), the actual contribution of distinct ph…”
BackgroundA Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy
Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00734-1 · Cited by 1,050
Self-citation
Cited by
Liu, D., & Hornsby, P. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3452 · Cited by 499
Ota, H., Tokunaga, E., Chang, K., Hikasa, M., Iijima, K., Eto, M., Kozaki, K., Akishita, M., Ouchi, Y., & Kaneki, M. (2006) · Oncogene · doi:10.1038/sj.onc.1209049 · Cited by 435
Pancreatic Cancer: Basic and Clinical Aspects
Schneider, G., Siveke, J. T., Eckel, F., & Schmid, R. M. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.001 · Cited by 289
Cellular senescence and cancer treatment
Schmitt, C. A. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.08.005 · Cited by 254
Self-citationDuan, J., Duan, J., Zhang, Z., & Tong, T. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.01.010 · Cited by 229
p53-independent regulation of p21Waf1/Cip1 expression and senescence by Chk2.
Aliouat-Denis, C.-M., Dendouga, N., Van den Wyngaert, I., Goehlmann, H., Steller, U., van de Weyer, I., Van Slycken, N., Andries, L., Kass, S., Luyten, W., et al. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0121 · Cited by 177
Fluctuations in p53 Signaling Allow Escape from Cell-Cycle Arrest
Reyes, J., Chen, J.-Y., Stewart-Ornstein, J., Karhohs, K. W., Mock, C. S., & Lahav, G. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.06.031 · Cited by 149
“This raises the possibility that therapyinduced senescent cells may constitute a latent cellular reservoir of damaged cells that could contribute to tumor repopulation and the emergence of resistance to DNA damaging therapies (Kahlem et al., 2004; Schmitt et al., 2002).”
Dong, C., Wang, X., Sun, L., Zhu, L., Yang, D., Gao, S., Zhang, W., Ling, B., Liang, A., Gao, Z., et al. (2022) · Stem Cell Research · doi:10.1016/j.scr.2021.102618 · Cited by 16
Metadata
- Authors
- Kahlem, P., Dörken, B., & Schmitt, C. A.
- Venue
- Journal of Clinical Investigation
- Publisher
- American Society for Clinical Investigation
- Published
- 2004-01-15
- Volume
- 113
- Issue
- 2
- Pages
- 169-174
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2037731733
- Cited by
- 119
- References
- 19
- FWCI
- 4.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.